Lorazepam | |
---|---|
Molecular structure via molpic based on CDK |
Conformer [] | |
---|---|
Conformer structure via JSmol |
Physical properties [] | |
---|---|
Molecular mass | 335.2 g/mol [1] |
Melting point | 206 °C [1] |
Predicted LogP | 2.4 [1] |
Structural Identifiers [] | |
---|---|
Molecular formula | C16H12Cl2N2O2 [1] |
IUPAC name | 7-chloro-5-(2-chlorophenyl)-3-hydroxy-1-methyl-3H-1,4-benzodiazepin-2-one [1] |
SMILES | CN1C2=C(C=C(C=C2)Cl)C(=NC(C1=O)O)C3=CC=CC=C3Cl [1] |
InChI | InChI=1S/C16H12Cl2N2O2/c1-20-13-7-6-9(17)8-11(13)14(19-15(21)16(20)22)10-4-2-3-5-12(10)18/h2-8,15,21H,1H3 [1] |
InChIKey | FJIKWRGCXUCUIG-UHFFFAOYSA-N [1] |
Dosing [] | |
---|---|
Elimination half-life | 10 – 12 hours |
Lorazepam
Lorazepam (also known as Lorazepam, Lormetazepam, Methyllorazepam, N-Methyllorazepam, Loramet, Noctamid, Lormetazepamum, Chlorotemazepam, Ergocalm or Noctamide) is a
Chemistry
Stereochemistry []
Lorazepam is a racemic mixture of the optical stereoisomers
Stereoisomers |
---|
Anodyne Usernotes [] | |
---|---|
0xea / Lorazepam via | Anxiety suppression; Strong memory suppression |
Legal status
- Brazil: Lorazepam is a B1 substance.[3]
- Canada: Lorazepam is a Schedule IV substance.
- Germany: Lorazepam is a prescription only/Anlage III substance.
- United States: Lorazepam is a Schedule I under the "Controlled Substances Act (CSA)".
See also []
External links []
References []
National Center for Biotechnology Information. PubChem Compound Summary for CID 13314, Lorazepam. Accessed July 11, 2025. https://pubchem.ncbi.nlm.nih.gov/compound/13314
U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Lorazepam. UNII: GU56C842ZA. Global Substance Registration System. Accessed July 11, 2025. https://gsrs.ncats.nih.gov/ginas/app/beta/substances/GU56C842ZA
Anvisa. RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial. Diário Oficial da União. March 31, 2023. Accessed July 11, 2025. https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992